Hematology/Oncology - Overview
The Division of Hematology/Oncology was formed when The Miriam Hospital Hematology/Oncology Division, the Rhode Island Hospital Division of Hematology and the Rhode Island Hospital Department of Medical Oncology merged in 1999. The division includes thirteen MD's, six PhD's, nurses, pharmacists, social workers, protocol nurses and staff, cancer registrars, lab technicians and secretaries. Our mission is to achieve academic excellence in basic research, clinical research and education, and to provide the highest quality of care to our patients.
At Rhode Island Hospital Dr. Douglas Hixson directs a laboratory studying mechanisms of carcinogenesis in hepatocellular carcinoma. Dr. Loren Fast studies the regulation of immune responses to allogeneic major histocompatibility complex (MHC) antigens.
Clinical research is conducted under the direction of the Brown University Oncology Group (BrUOG), which is chaired by Dr. Howard Safran. Patients are offered state of the art cancer chemotherapy protocols, both via national cooperative groups as well as our own local protocols.
Brown Medical School has an active and productive fellowship program. Under the leadership of Dr. Humera Khurshid, we have fifteen fellows who spend three years gaining board eligibility in both Hematology and Medical Oncology. During their stay in the program, the fellows gain expertise not only in the clinical management of patients, but also in writing and implementing clinical trials for cancer patients.
The Division of Hematology/Oncology provides a full range of services to patients both in the ambulatory and hospital settings. At both The Miriam Hospital and Rhode Island Hospital, newly renovated outpatient space allows for the diagnosis and treatment of the entire range of hematologic and oncologic disorders. Dedicated inpatient units at hospitals allow nursing expertise and other support services to best meet our patients' needs. A recent goal has been the establishment of multidisciplinary clinics for all the major malignancies. This allows the patient to receive the expertise of the surgeon, radiation oncologist and medical oncologist at the time of their first visit.